index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

79

 

NOTICES

153

 

 

MOTS CLES

Bacterial rhinosinusitis Cardiomyopathy Adolescent Sacroiliitis Biological Therapy Infliximab Biologic Endocrine toxicity Adverse side effects Biomédicaments Alcohol Vigibase® Treatment Antibiotic resistance Biologic drug Axial spondyloarthritis Ethics Anti-HCV Direct Acting Antivirals DAA Anxiety Drug reaction Cardiovascular therapy Cardiovascular risk Autoimmunity Beta-lactam antibiotics BTK protein Quality of life Antimicrobials Pharmacovigilance Arthritis Albinism Ankylosing Pharmacoepidemiology Méta-Analyse Placebo Auto-Diagnostic Psoriasis Antibiotic misuse Atrial fibrillation Stability Ankylosing spondylitis Access to care Dermatology Biologics Autoimmune diseases Etanercept Anti-TNF Spondyloarthritis ASDAS Atopic dermatitis Biomarkers Acute Myeloid Leukaemia AML Biological therapy Anticancer drugs Intensive care Adalimumab Addiction Cardio-oncology Angiotensin receptor blockers Accelerometer Graft-versus-host disease Primary adrenal insufficiency Epidemiology Cancer Alitretinoin Amyloidosis Immunotherapy COVID-19 Immune checkpoint inhibitors Cardiotoxicity Prostate cancer Apre-milast Antimicrobiens Drug survival CSK tyrosine-protein kinase Immune-related adverse events Meta-Analysis Care pathway Antibiotics Cattle Management Arrhythmia Biosimilar Pharmaceuticals Abus d'antibiotiques Case-Control Studies Antimicrobial resistance Psoriatic arthritis Azathioprine Apremilast Aging ArtThese Auto-immune hepatitis Calcium channel blockers Ustekinumab Burden CTLA-4 Angiotensin-converting enzyme inhibitors Biologic therapy Anxiété Glucocorticoids Sipuleucel-T

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS